MN-IMRICOR
Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005630/en/
Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI
Under the terms of the MOU, GE HealthCare and Imricor intend to collaborate to interface Imricor’s Advantage-MR EP Recorder/Stimulator and Northstar-MR 3D Mapping System with GE HealthCare MRI scanners. A successful collaboration will enable cardiac electrophysiology (EP) ablation procedures guided by real-time MRI, using Imricor’s catheters and other disposable devices, to be performed on the GE HealthCare MRI platform. The collaboration with GE HealthCare would expand Imricor’s potential to interface with GE HealthCare’s new and currently installed MRI scanners.
Imricor’s short-term goal is to allow sites with GE HealthCare MRI systems to participate in the upcoming “Vision-MR Ablation of Atrial FLutter” or VISABL-AFL clinical trial in the US and “Vision-MR Ablation of Ventricular Tachycardia” or VISABL-VT clinical trial in Europe. The Company’s overall goal is to broaden in the choices physicians and hospitals have when choosing an MRI platform for their iCMR labs.
“Imricor’s innovative technology has the potential to bring significant benefit to a large number of cardiac arrhythmia patients,” said Anja Brau, PhD, General Manager, GE HealthCare MR Clinical Solutions and Research Collaborations. “GE HealthCare has a long-standing history of applying MR to therapy guidance and control; we would be pleased to add Imricor’s capabilities to provide our customers with more options to treat their patients.”
“We are thrilled at the prospect of expanding the portfolio of MRI scanners that support Advantage-MR and Northstar-MR technology,” said Steve Wedan, Imricor’s CEO and Chair. “The addition of GE HealthCare will give physicians and hospitals significantly more flexibility to use the MRI hardware of their choice, when providing real-time iCMR ablations for their patients. We are grateful to our existing customers who have embraced our real-time iCMR ablation technology, and look forward to making the benefits of this technology even more widely available.”
About Imricor
Please visit http://imricor.com/investors/about-imricor/ for more information about Imricor, Foreign Ownership Restrictions, and Forward-Looking Statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005630/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Third Quarter and Nine-Month 2025 Earnings19.11.2025 22:05:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2025 results on Tuesday, November 25, 2025. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, 3:00 p.m. Morocco (GMT+1), and 2:00 p.m. London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2025 results at 10:00 a.m. EDT, 4:00 p.m. Morocco (GMT+1), and 3:00 p.m. London time (GMT) on Tuesday, November 25, 2025, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s
Marquee Brands Broadens Global Portfolio with Strategic Acquisition of Stance19.11.2025 21:00:00 CET | Press release
Marquee’s 19th Brand Signals a Bold Expansion into Lifestyle and Performance Marquee Brands, the premier global brand accelerator, today announced the acquisition of Stance, the innovative lifestyle and performance sock brand. Founded in 2009 in San Clemente, California, Stance joins Marquee Brands’ renowned portfolio, home to some of the world’s most notable brands, including Martha Stewart, Laura Ashley, Sur La Table, BCBG, Ben Sherman, Body Glove and Dakine. The addition of Stance brings total retail sales across Marquee’s portfolio to $4.5 Billion USD. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119216623/en/ Marquee also announces a new partnership with United Legwear and Apparel Co. (ULAC), which becomes the brand’s core global licensee, managing operations across all territories apart from China. With products sold in 42 countries through more than 1,100 U.S. wholesale accounts, e-commerce, international distrib
AWS and HUMAIN Expand Partnership with NVIDIA AI Infrastructure and AWS AI Chip Deal to Drive Global AI Innovation19.11.2025 19:38:00 CET | Press release
Expanded partnership includes deployment of up to 150,000 AI accelerators including the latest NVIDIA GB300s AI infrastructure and AWS’s Trainium chips.Amazon Bedrock will provide customers access to best-in-class foundation models optimized across diverse, high performance AI chip infrastructures.AWS becomes HUMAIN’s preferred AI partner with AWS and HUMAIN collaborating to bring AI compute and services to customers worldwide. Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and HUMAIN, a Public Investment Fund (PIF) company delivering global full-stack AI solutions, announced today at the U.S.-Saudi Investment Forum their plans to provide, deploy and manage up to 150,000 AI accelerators in a data center facility known as an “AI Zone” in Riyadh. As part of the expanded partnership, AWS will become HUMAIN’s preferred AI partner globally, and the two companies will collaborate to bring AI compute and services from Saudi Arabia to customers worldwide. This pre
Luma AI Raises $900 Million Series C Led by HUMAIN And Partners on 2 Gigawatt AI Supercluster in Saudi Arabia19.11.2025 18:15:00 CET | Press release
New capital and compute infrastructure will accelerate Luma AI’s path towards Multimodal AGI – AI that can simulate reality and help humans in the physical world.HUMAIN to build Project Halo, one of the world’s largest AI compute clusters that will include the training of World Models, the next step in AI after LLMs - a potential trillion-dollar opportunity spanning entertainment, marketing/brands, education, world understanding, and robotics industries.Partnership includes HUMAIN Create, an initiative to build AI models trained on Arabic and regional data, helping enterprises and governments across MENA adopt culturally aligned AI. Luma AI, the frontier artificial intelligence company building multimodal AGI, today announced it has raised $900 million in Series C funding, led by HUMAIN, a PIF company delivering global full-stack AI solutions, with significant participation from AMD Ventures, and existing investors Andreessen Horowitz, Amplify Partners, and Matrix Partners. This press
Synthio Labs Raises $5 Million to Build the Voice AI Operating System for Life Sciences Customer Engagement19.11.2025 16:00:00 CET | Press release
Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, today announced that it has raised $5 million in seed funding. The round was led by Elevation Capital with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and several strategic angels from the global healthcare and AI ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119509940/en/ Rajashekar Vasantha (left), Supreet Deshpande (center), and Sahitya Sridhar (right), the founding team behind Synthio Labs’ voice-powered AI platform for pharma “We believe Synthio Labs is defining the next major Customer Engagement infrastructure for Life Sciences. Their Clinical-grade Voice AI platform unifies how pharma communicates - giving field teams a powerful voice companion, and giving physicians and patients instant, trusted, compliant answers 24/7. Pharma’s global Commercial and GTM foo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom